Gemphire Therapeutics Inc. (GEMP) Rating Reiterated by HC Wainwright

Gemphire Therapeutics Inc. (NASDAQ:GEMP)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Tuesday. They currently have a $22.00 price objective on the stock, up from their previous price objective of $21.00. HC Wainwright’s price target would indicate a potential upside of 136.81% from the company’s current price.

Several other equities analysts have also commented on GEMP. Zacks Investment Research raised Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Wednesday, July 19th. Canaccord Genuity set a $31.00 price objective on Gemphire Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 26th. Finally, Jefferies Group LLC raised their price objective on Gemphire Therapeutics to $32.00 and gave the company a “buy” rating in a research report on Tuesday, August 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $22.17.

Shares of Gemphire Therapeutics (NASDAQ:GEMP) traded up $0.11 during mid-day trading on Tuesday, reaching $9.29. The company had a trading volume of 24,400 shares, compared to its average volume of 67,652. Gemphire Therapeutics has a 12 month low of $7.20 and a 12 month high of $21.59.

Gemphire Therapeutics (NASDAQ:GEMP) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.14). analysts expect that Gemphire Therapeutics will post -3.17 EPS for the current fiscal year.

WARNING: “Gemphire Therapeutics Inc. (GEMP) Rating Reiterated by HC Wainwright” was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.themarketsdaily.com/2017/11/16/gemphire-therapeutics-inc-gemp-rating-reiterated-by-hc-wainwright.html.

Large investors have recently modified their holdings of the company. Advisory Services Network LLC bought a new position in shares of Gemphire Therapeutics during the second quarter valued at $139,000. Renaissance Technologies LLC bought a new position in shares of Gemphire Therapeutics during the first quarter valued at $184,000. Vanguard Group Inc. increased its holdings in shares of Gemphire Therapeutics by 137.6% during the second quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock valued at $399,000 after acquiring an additional 17,892 shares in the last quarter. GM Advisory Group Inc. bought a new position in shares of Gemphire Therapeutics during the second quarter valued at $457,000. Finally, Comerica Bank bought a new position in shares of Gemphire Therapeutics during the third quarter valued at $850,000. Hedge funds and other institutional investors own 32.91% of the company’s stock.

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply